Protection of estrogens against the progression of chronic liver disease

Hepatology Research

Volumn 37, Issue 4, 2007, Pages 239-247

  Shimizu, Ichiro ^a   Ito, Susumu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Estradiol; Estrogen receptor; Hepatic fibrosis; Hepatic stellate cell; Menopause; Oxidative stress

Indexed keywords

AROMATASE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; REACTIVE OXYGEN METABOLITE; TAMOXIFEN; TESTOSTERONE;

ALCOHOL LIVER DISEASE; BIOSYNTHESIS; BREAST CANCER; CELL ACTIVATION; CHRONIC LIVER DISEASE; CLINICAL FEATURE; DISEASE COURSE; ENZYME DEFICIENCY; ESTROGEN ACTIVITY; EXTRACELLULAR MATRIX; FATTY LIVER; HEPATITIS C; HUMAN; INFLAMMATION; LIPID PEROXIDATION; LIVER CELL; LIVER CIRRHOSIS; LIVER PROTECTION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATION; PATHOPHYSIOLOGY; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; STELLATE CELL; TESTIS DISEASE;

EID: 33947720284     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00032.x     Document Type: Review

References (93)

1. McMahon BJ, Alberts SR, Wainwright RB et al. Hepatitis B-related sequelae: Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med 1990; 150: 1051-4.
2. Poynard T, Ratziu V, Charlotte F et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-9.
3. Shimizu I. Impact of estrogens on the progression of liver disease. Liver Int 2003; 23: 63-9.
4. Takano S, Yokosuka O, Imazeki F et al. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients. Hepatology 1995; 21: 650-5.
5. Shiratori Y, Shiina S, Imamura M et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan. Hepatology 1995; 22: 1027-33.
6. Zaman SN, Melia WM, Johnson RD et al. Risk factors in development of hepatocellular carcinoma in cirrhosis: Prospective study of 613 patients. Lancet 1985; 1: 1357-60.
7. Villa E, Baldini GM, Pasquinelli C et al. Risk factors for hepatocellular carcinoma in Italy. Male sex, hepatitis B virus, non-A non-B infection, and alcohol. Cancer 1988; 62: 611-15.
8. Shimizu I, Inoue H, Yano M et al. Estrogen receptor levels and lipid peroxidation in hepatocellular carcinoma with hepatitis C virus infection. Liver 2001; 21: 342-9.
9. Harrison SA, Kadakia S, Lang KA et al. Non-alcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol 2002; 97: 2714-24.
10. Weltman MD, Farrell GC, Hall P et al. Hepatic cytochrome P450 2E1 is increased in patients with non-alcoholic steatohepatitis. Hepatology 1998; 27: 128-33.
11. Clark JM, Brancati FL, Diehl AM. Non-alcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-57.
12. Poli G. Pathogenesis of liver fibrosis: Role of oxidative stress. Mol Aspects Med 2000; 21: 49-98.
13. Pinkus R, Weiner LM, Daniel V. Role of oxidants and antioxidants in the induction of AP-1, NF-kappaB, and glutathione S-transferase gene expression. J Biol Chem 1996; 271: 13422-9.
14. Clement MV, Pervaiz S. Reactive oxygen intermediates regulate cellular response to apoptotic stimuli: An hypothesis. Free Radic Res 1999; 30: 247-52.
15. Lundberg AS, Hahn WC, Gupta P et al. Genes involved in senescence and immortalization. Curr Opin Cell Biol 2000; 12: 705-9.
16. Lee KS, Buck M, Houglum K et al. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest 1995; 96: 2461-8.
17. Parola M, Pinzani M, Casini A et al. Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen (I) gene expression in human liver fat-storing cells. Biochem Biophys Res Commun 1993; 194: 1044-50.
18. Olynyk JK, Khan NA, Ramm GA et al. Aldehydic products of lipid peroxidation do not directly activate rat hepatic stellate cells. J Gastroenterol Hepatol 2002; 17: 785-90.
19. Cui X, Shimizu I, Lu G et al. Inhibitory effect of a soluble transforming growth factor β type II receptor on the activation of rat hepatic stellate cells in primary culture [see comments]. J Hepatol 2003; 39: 731-7.
20. De Bleser PJ, Xu G, Rombouts K et al. Glutathione levels discriminate between oxidative stress and transforming growth factor-beta signaling in activated rat hepatic stellate cells. J Biol Chem 1999; 274: 33881-7.
21. Itagaki T, Shimizu I, Cheng X et al. Opposing effects of oestradiol and progesterone on intracellular pathways and activation processes in the oxidative stress induced activation of cultured rat hepatic stellate cells. Gut 2005; 54: 1782-9.
22. Yoshino K, Komura S, Watanabe I et al. Effect of estrogens on serum and liver lipid peroxide levels in mice. J Clin Biochem Nutr 1987; 3: 233-9.
23. Lacort M, Leal AM, Liza M et al. Protective effect of estrogens and catecholestrogens against peroxidative membrane damage in vitro. Lipids 1995; 30: 141-6.
24. Omoya T, Shimizu I, Zhou Y et al. Effects of idoxifene and estradiol on NF-kappaB activation in cultured rat hepatocytes undergoing oxidative stress. Liver 2001; 21: 183-91.
25. Inoue H, Shimizu I, Lu G et al. Idoxifene and estradiol enhance antiapoptotic activity through the estrogen receptor-β in cultured rat hepatocytes. Dig Dis Sci 2003; 48: 570-80.
26. Paech K, Webb P, Kuiper GG et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997; 277: 1508-10.
27. Zhou Y, Shimizu I, Lu G et al. Hepatic stellate cells contain the functional estrogen receptor beta but not the estrogen receptor alpha in male and female rats. Biochem Biophys Res Commun 2001; 286: 1059-65.
28. Cheng X, Shimizu I, Yuan Y et al. Effects of estradiol and progesterone on tumor necrosis factor alpha-induced apoptosis in human hepatoma HuH-7 cells. Life Sci 2006; 79: 1988-94.
29. Kage M, Shimamatu K, Nakashima E et al. Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C: morphometric analysis of repeated biopsies. Hepatology 1997; 25: 1028-31.
30. Shimizu I, Omoya T, Kondo Y et al. Estrogen therapy in a male patient with chronic hepatitis C and irradiation-induced testicular dysfunction. Intern Med 2001; 40: 100-4.
31. Datz C, Cramp M, Haas T et al. The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre. Gut 1999; 44: 563-7.
32. Kim WR, Poterucha JJ, Benson JT et al. The impact of competing risks on the observed rate of chronic hepatitis C progression. Gastroenterology 2004; 127: 749-55.
33. Ryder SD, Irving WL, Jones DA et al. Progression of hepatic fibrosis in patients with hepatitis C: A prospective repeat liver biopsy study. Gut 2004; 53: 451-5.
34. Hayashi H, Takikawa T, Nishimura N et al. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994; 89: 986-8.
35. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997; 25: 759-68.
36. Shimizu I, Omoya T, Takaoka T et al. Serum aminoterminal propeptide of type III procollagen and 7S domain of type IV collagen correlate with hepatic iron concentration in patients with chronic hepatitis C following alpha-interferon therapy. J Gastroenterol Hepatol 2001; 16: 196-201.
37. Farinati F, Cardin R, De Maria N et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995; 22: 449-56.
38. George DK, Goldwurm S, MacDonald GA et al. Increased hepatic iron concentration in non-alcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-18.
39. Yasuda M, Shimizu I, Shiba M et al. Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats [see comments]. Hepatology 1999; 29: 719-27.
40. Shimizu I, Mizobuchi Y, Shiba M et al. Inhibitory effect of estradiol on activation of rat hepatic stellate cells in vivo and in vitro. Gut 1999; 44: 127-36.
41. Lu G, Shimizu I, Cui X et al. Antioxidant and antiapoptotic activities of idoxifene and estradiol in hepatic fibrosis in rats. Life Sci 2004; 74: 897-907.
42. Pinzani M, Failli P, Ruocco C et al. Fat-storing cells as liver-specific pericytes. Spatial dynamics of agonist-stimulated intracellular calcium transients. J Clin Invest 1992; 90: 642-6.
43. Bataller R, Gines P, Nicolas JM et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000; 118: 1149-56.
44. Rockey DC, Housset CN, Friedman SL. Activation-dependent contractility of rat hepatic lipocytes in culture and in vivo. J Clin Invest 1993; 92: 1795-804.
45. Sakamoto M, Ueno T, Kin M et al. Ito cell contraction in response to endothelin-1 and substance P. Hepatology 1993; 18: 978-83.
46. Rockey D. The cellular pathogenesis of portal hypertension: Stellate cell contractility, endothelin, and nitric oxide. Hepatology 1997; 25: 2-5.
47. Arai H, Hori S, Aramori I et al. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348: 730-2.
48. Sakurai T, Yanagisawa M, Takuwa Y et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990; 348: 732-5.
49. Rockey DC, Chung JJ. Inducible nitric oxide synthase in rat hepatic lipocytes and the effect of nitric oxide on lipocyte contractility. J Clin Invest 1995; 95: 1199-206.
50. Helyar L, Bundschuh DS, Laskin JD et al. Induction of hepatic Ito cell nitric oxide production after acute endotoxemia. Hepatology 1994; 20: 1509-15.
51. Shah V, Haddad FG, Garcia-Cardena G et al. Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids. J Clin Invest 1997; 100: 2923-30.
52. Sakamoto M, Ueno T, Nakamura T et al. Estrogen upregulates nitric oxide synthase expression in cultured rat hepatic sinusoidal endothelial cells. J Hepatol 2001; 34: 858-64.
53. Itagaki T, Shimizu I, Yuan Y et al. Estradiol inhibits endothelin receptor expression and cell contraction in cultured rat hepatic stellate cells. Gastroenterology 2005; 128: A-729.
54. Lieber CS. Medical disorders of alcoholism. N Engl J Med 1995; 333: 1058-65.
55. Ikejima K, Enomoto N, Iimuro Y et al. Estrogen increases sensitivity of hepatic Kupffer cells to endotoxin. Am J Physiol 1998; 274: G669-G676.
56. Poynard T, Mathurin P, Lai CL et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38: 257-65.
57. Pfeilschifter J, Koditz R, Pfohl M et al. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 2002; 23: 90-119.
58. Rogers A, Eastell R. The effect of 17beta-estradiol on production of cytokines in cultures of peripheral blood. Bone 2001; 29: 30-4.
59. Kishihara Y, Hayashi J, Yoshimura E et al. IL-1 beta and TNF-alpha produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C. Dig Dis Sci 1996; 41: 315-21.
60. Kilbourne EJ, Scicchitano MS. The activation of plasminogen activator inhibitor-1 expression by IL-1beta is attenuated by estrogen in hepatoblastoma HepG2 cells expressing estrogen receptor alpha. Thromb Haemost 1999; 81: 423-7.
61. Ozveri ES, Bozkurt A, Haklar G et al. Estrogens ameliorate remote organ inflammation induced by burn injury in rats. Inflamm Res 2001; 50: 585-91.
62. Shiraishi T, Shimizu I, Itagaki T et al. Inhibitory effects of estrogen on chemokine and proinflammatory cytokine production in mononuclear cells and macrophages. Gastroenterology 2006; 150: A-793.
63. Schultze RL, Gangopadhyay A, Cay O et al. Tyrosine kinase activation in LPS stimulated rat Kupffer cells. Cell Biochem Biophys 1999; 30: 287-301.
64. Zuckerman SH, Bryan-Poole N, Evans GF et al. In vivo modulation of murine serum tumour necrosis factor and interleukin-6 levels during endotoxemia by oestrogen agonists and antagonists. Immunology 1995; 86: 18-24.
65. Scheuer PJ, Ashrafzadeh P, Sherlock S et al. The pathology of hepatitis C. Hepatology 1992; 15: 567-71.
66. Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: A comparative analysis. Hepatology 1992; 15: 572-7.
67. Lefkowitch JH, Schiff ER, Davis GL et al. Pathological diagnosis of chronic hepatitis C: A multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology 1993; 104: 595-603.
68. Moriya K, Yotsuyanagi H, Shintani Y et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997; 78: 1527-31.
69. Moriya K, Fujie H, Shintani Y et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4: 1065-7.
70. Gressner AM, Lotfi S, Gressner G et al. Identification and partial characterization of a hepatocyte-derived factor promoting proliferation of cultured fat-storing cells (parasinusoidal lipocytes). Hepatology 1992; 16: 1250-66.
71. Adinolfi LE, Gambardella M, Andreana A et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
72. Letteron P, Duchatelle V, Berson A et al. Increased ethane exhalation, an in vivo index of lipid peroxidation, in alcohol-abusers. Gut 1993; 34: 409-14.
73. Letteron P, Fromenty B, Terris B et al. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1996; 24: 200-8.
74. Berson ABV, Letteron P et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 1998; 114: 764-74.
75. Bellentani S, Saccoccio G, Masutti F et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-17.
76. Omagari K, Kadokawa Y, Masuda J et al. Fatty liver in non-alcoholic non-overweight Japanese adults: Incidence and clinical characteristics. J Gastroenterol Hepatol 2002; 17: 1098-105.
77. Toth MJ, Tchernof A, Sites CK et al. Effect of menopausal status on body composition and abdominal fat distribution. Int J Obes Relat Metab Disord 2000; 24: 226-31.
78. Elbers JM, Asscheman H, Seidell JC et al. Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals. Am J Physiol 1999; 276: E317-E25.
79. Haarbo J, Marslew U, Gotfredsen A et al. Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism 1991; 40: 1323-6.
80. Nemoto Y, Toda K, Ono M et al. Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice. J Clin Invest 2000; 105: 1819-25.
81. Van HM, Rahier J, Horsmans Y. Tamoxifen-induced steatohepatitis. Ann Intern Med 1996; 124: 855-6.
82. Oien KA, Moffat D, Curry GW et al. Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet 1999; 353: 36-7.
83. Villa E, Camellini L, Dugani A et al. Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma. Cancer Res 1995; 55: 498-500.
84. Villa E, Dugani A, Moles A et al. Variant liver estrogen receptor transcripts already occur at an early stage of chronic liver disease. Hepatology 1998; 27: 983-8.
85. Pinzani M, Romanelli RG, Magli S. Progression of fibrosis in chronic liver diseases: Time to tally the score. J Hepatol 2001; 34: 764-7.
86. Vargas R, Wroblewska B, Rego A et al. Oestradiol inhibits smooth muscle cell proliferation of pig coronary artery. Br J Pharmacol 1993; 109: 612-17.
87. Lindner V, Kim SK, Karas RH et al. Increased expression of estrogen receptor-beta mRNA in male blood vessels after vascular injury. Circ Res 1998; 83: 224-9.
88. Bayard F, Clamens S, Meggetto F et al. Estrogen synthesis, estrogen metabolism, and functional estrogen receptors in rat arterial smooth muscle cells in culture. Endocrinology 1995; 136: 1523-9.
89. Iafrati MD, Karas RH, Aronovitz M et al. Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nat Med 1997; 3: 545-8.
90. Kwan G, Neugarten J, Sherman M et al. Effects of sex hormones on mesangial cell proliferation and collagen synthesis. Kidney Int 1996; 50: 1173-9.
91. Colditz GA, Hankinson SE, Hunter DJ et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589-93.
92. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047-59.
93. Alvaro D, Alpini G, Onori P et al. Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats. Gastroenterology 2000; 119: 1681-91.